Population-based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea, 1999-2009

Abstract

PurposePrimary central nervous system lymphoma (PCNSL) is an uncommon brain tumor accounting for 2%-5% of all primary brain tumors. Few population-based analyses of survival for patients with PCNSL have been conducted, particularly in Asian countries.Materials and MethodsUsing the Korea National Cancer Incidence Database, 1,062 cases of PCNSL newly diagnosed from 1999 to 2009 were analyzed. The crude rate, age-standardized rate (ASR), and annual percent change were calculated. To estimate the observed survival, we restricted the data to between 1999 and 2007 and followed the cases until December 2010. The overall survival was estimated using the Kaplan-Meier method, and piecewise Poisson regression model.ResultsThe ASR for PCNSL between 1999 and 2009 was 0.17 per 100,000, and the annual percent change from 1999 to 2009 was 8.8% (p < 0.001). The ASR of males was higher than that of females, and the older groups (60s or over) showed the largest increase in incidence rates. For all ages, the five-year survival from PCNSL was 29.9% between 1999 and 2007. Survival from PCNSL is known to show strong association with age at diagnosis.ConclusionThese results are similar to those of previous studies. Our findings may be helpful to clinicians and patients in determining long-term prognoses for PCNSL.

Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study

“…This pattern somewhat mirrored, yet lagged behind, that observed in the United States; according to United States population data spanning an overlapping calendar period, there was a similar rapid increase in rate during the 1980s, followed by a relative plateau [ 30 ]. The incidence of PCNSL is higher in men than women in Australia, consistent with observations from other population-based cohorts [ 2 , 10 , 12 ].…”

“…Present incidence of PCNSL in the Australian population is greater than that reported for Korea (i.e., 0.25 per 100,000 person-years) [ 10 ], but consistent with figures reported in Japanese, Spanish, French, Irish, Swedish, Dutch, and North American population studies, which range between 0.4 and 0.5 per 100,000 person-years [ 2 , 11 , 12 , 13 , 27 , 28 , 29 ]. While reports from Western Europe and Asia indicate ongoing annual increases [ 9 , 10 , 11 , 12 , 13 , 27 ], incidence of PCNSL has plateaued in the United States [ 30 ]. The overall increase in incidence of PCNSL in Australia that we have observed, was characterized by a rapid ‘jump’ in the rate in the 1990s, which was most apparent for persons aged 70–79 years, after which the rate plateaued.…”

“…Population-based studies offer the most accurate representation of the epidemiology of PCNSL in the general population. A small number of population-based surveys have been published, including from countries in Asia, Western Europe, and North America; the annual incidence of PCNSL across these regions during time periods spanning 1975 to 2015 ranges from 1 to 4 per million persons, and several studies suggest the incidence is increasing [ 2 , 9 , 10 , 11 , 12 , 13 ].…”

Outcome and prognostic factors of primary central nervous system lymphoma in Southern Thailand

“…In contrast, previous studies found that older age and pretreatment PS are significant prognostic factors. [ 2 3 5 6 10 11 13 14 ] Most previous studies defined older age as >60 years,[ 3 6 13 16 17 18 ] whereas others used >50 years as the cut off. [ 2 5 11 14 ] In our study, older age was a significant predictor of poor outcomes in the univariable analysis, and age was a poor prognostic factor, but not significant, in the multivariable analysis.…”

“…[ 1 ] The disease incidence is more common in immunocompromised patients. [ 2 3 ] However, this rate has increased in healthy elderly within the current decade. [ 4 ]…”